CUSTOM RECOMBINANT PROTEIN PRODUCTION SERVICES MARKET ANALYSIS

Custom Recombinant Protein Production Services MarketSize and Trends

The global custom recombinant protein production services market is estimated to be valued at US$ 4.9 billion in 2023 and is expected to exhibit a CAGR of 11.5% during the forecast period (2023-2030).

Market Size in 2023: US$ 4.9 Bn

Forecast Period: 2023 to 2030

Forecast Period 2023 to 2030 CAGR: 11.5%

2030 Value Projection: US$ 10.5 Bn

Figure 1. Global Custom Recombinant Protein Production Services Market Share (%), By Expression System, 2023

Global Custom Recombinant Protein Production Services Market– Drivers

• Increasing prevalence of diseases such as diabetes, cancer, heart disorders: Recombinant proteins include recombinant hormones, growth factors, interferons, interleukins, blood clotting factors, tumor necrosis factors, thrombolytic drugs, and enzymes for treating major diseases such as diabetes, dwarfism, congestive heart failure, myocardial infarction, cerebral apoplexy, neutropenia, multiple sclerosis, thrombocytopenia, hepatitis, anemia, Crohn’s disease, rheumatoid arthritis, asthma, and cancer, which is expected to drive market growth over the forecast period. Moreover, recombinant proteins are used for the development of vaccines, which can help treat and prevent autoimmune diseases such as rheumatoid arthritis and inflammatory bowel diseases (IBD), Thus, the increasing prevalence of such diseases is expected to drive market growth. For instance, according to the data provided by Breastcancer.org, is an education and support lifeline for millions of people affected by breast cancer in March 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 51,400 new cases of non-invasive (in situ) breast cancer.
• Increasing research and development activities for the development of recombinant protein-based products by the key players in the market: Recombinant proteins help to understand the basic and fundamental principles of an organism. They are used to identify and locate the position of the protein encoded by a specific gene and to identify the function of other genes in various cellular activities such as cell signaling, growth, metabolism, replication and death, transcription, translation, and protein modification. For instance, in February 2022, CORBEVAX, an indigenously developed receptor binding domain (RBD) recombinant protein sub-unit vaccine for COVID-19, developed by Biological E Limited, a biotechnology and biopharmaceutical company, received approval for emergency use authorization from the Drug Controller General of India (DCGI) for the 12-18 age group. The Department of Biotechnology (DBT) and its Public Sector Undertaking (PSU), the Biotechnology Industry Research Assistance Council (BIRAC), had supported the company’s COVID-19 vaccine candidate from the pre-clinical stage through Phase III clinical studies.

Figure 2. Global Custom Recombinant Protein Production Services Market Share (%), By Region, 2023

Global Custom Recombinant Protein Production Services Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdown in various countries across the globe have positively impacted the financial status of businesses across all sectors. The biotechnology sector is one such sector that has been heavily impacted by the pandemic.

However, governments of various countries are focusing on initiatives to fight against the COVID-19 pandemic and stop the spread of the coronavirus infection by implementing various measures in their countries. Countries such as the U.A.E., the U.K., and others have implemented some measures and guidelines to reduce the spread of COVID-19 in their countries. For instance, in December 2021, the Ministry of Health and Prevention (MoHAP) U.A.E. approved the emergency use of Sinopharm CNBG's (China National Biotec Group) new recombinant protein vaccine, following the strict monitoring and evaluation of the data of the study conducted in the U.A.E. The ministry affirmed that the emergency use of the new vaccine is in full compliance with the regulations and laws for a faster review of licensing procedures. This was a part of the ministry's painstaking efforts, in the cooperation with health authorities, to help in prevention of the COVID-19 pandemic among people.